The Claim
In obese mice on a high-fat diet, 8 weeks of empagliflozin treatment improves insulin sensitivity by enhancing insulin-stimulated phosphorylation of Akt and insulin receptor β in adipose tissue, liver, and muscle, and by reducing fasting insulin levels.
What the research says
Supports is higher
Support is ahead, but a single strong opposing study can change this.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
In obese mice fed a high-fat diet, 8 weeks of empagliflozin treatment increases insulin sensitivity, as measured by higher phosphorylation of Akt and insulin receptor β in fat, liver, and muscle tissues, and lower fasting insulin levels.
See the scientific wording
In obese mice on a high-fat diet, empagliflozin treatment for 8 weeks improved insulin sensitivity, as shown by enhanced insulin-stimulated phosphorylation of Akt and insulin receptor β in adipose tissue, liver, and muscle, and reduced fasting insulin levels, indicating a reversal of insulin resistance.
Empagliflozin causes the kidneys to remove excess sugar in urine, which forces the body to burn more fat for energy. This triggers fat cells to become more active and generate heat, while immune cells in fat tissue switch from causing inflammation to reducing it. These changes improve how insulin works in fat, liver, and muscle, lowering blood sugar and insulin levels.
What the research says
1 studyIn obese mice, a diabetes drug called empagliflozin helped their bodies use insulin better, lowered their insulin levels, and made their fat and liver healthier — even without them losing all the weight.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.